Another single-institution phase I study is investigating the use of a pooled mutant-KRAS peptide vaccine with poly-ICLC adjuvant in combination with nivolumab and ipilimumab in the first-line treatment of advanced NSCLC (NCT05254184). This evidence concerns the gene KRAS and non-small cell lung carcinoma.